The FDA has approved Ixabepilone (Ixempra) as a monotherapy and in combination with capecitabine
(Xeloda) for patients with metastic or locally advanced breast cancer.
This breast cancer drug is first in new class of chemo agents
Submitted by eport on Mon, 12/10/2007 - 05:00.
»
- Login or register to post comments
- Feed: New Rx: Drug Topics
- Original article